This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Riechelmann, R. P. Articles by Krzyzanowska, M. K. Search for Related Content PubMed PubMed Citation Articles by Riechelmann, R. P. Articles by Krzyzanowska, M. K. Related Articles Related Correspondence Social Bookmarking                            What's this?

Disclosure of Conflicts of Interest by Authors of Clinical Trials and Editorials in Oncology

Rachel P. Riechelmann, Lisa Wang, Aoife O'Carroll, Monika K. Krzyzanowska

From the Department of Medical Oncology, Albert Einstein Hospital, Sao Paulo, Brazil; and Departments of Biostatistics and Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada

Address reprint requests to Monika K. Krzyzanowska, MD, MPH, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Ste 5-206, Toronto, Ontario M5G 2M9, Canada; e-mail: Monika.Krzyzanowska{at}uhn.on.ca

Purpose There is concern that financial relationships between sponsors and investigators may bias research results. Our objective was to evaluate the epidemiology of conflicts of interest (COIs) among authors of clinical trials and editorials in oncology and the relationship between COI disclosure and source of funding.

Methods We did a cross-sectional survey of clinical trials and editorials of anticancer agents and supportive care medications published in the Journal of Clinical Oncology (JCO) during a 1-year period.

Results Of 1,533 articles published in JCO between January 1, 2005, and January 31, 2006, 332 met our inclusion criteria; 289 (87%) were clinical trials, and 43 (13%) were editorials. The pharmaceutical industry entirely or partially funded 44% of the clinical trials. At least one COI was disclosed in 69% of clinical trials and 51% of editorials. The most common types of COI reported by authors were consultancy fees, honoraria, and research funds. The highest monetary levels of interest reported by authors were for research grants, but the majority of authors with COIs received less than US$10,000. In multivariable analysis, authors of clinical trials conducted in North America (North America v Europe: odds ratio [OR] = 2.9, P = .002) and authors of trials funded entirely (industry only v nonprofit: OR = 13.8, P < .001) or partially (both industry and nonprofit v nonprofit only: OR = 5.8, P < .001) by industry were more likely to report personal COIs.

Conclusion COIs are common in clinical cancer research and usually take the form of consultancy fees, honoraria, and research funds. Source of study funding was significantly associated with COI disclosure.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Disclosure of Financial Conflicts of Interest by Authors Publishing in the Journal of Clinical Oncology
  Ronald S. Go, Michelle A. Mathiason, and Jennifer A. Lee
  JCO 2008 26: 509-510 [Full Text]

This article has been cited by other articles:

				A. S. Kesselheim, A. S. Misono, J. L. Lee, M. R. Stedman, M. A. Brookhart, N. K. Choudhry, and W. H. Shrank Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular Disease: A Systematic Review and Meta-analysis JAMA, December 3, 2008; 300(21): 2514 - 2526. [Abstract] [Full Text] [PDF]

				R. S. Go, M. A. Mathiason, and J. A. Lee Disclosure of Financial Conflicts of Interest by Authors Publishing in the Journal of Clinical Oncology J. Clin. Oncol., January 20, 2008; 26(3): 509 - 510. [Full Text] [PDF]

				R. P. Riechelmann and M. K. Krzyzanowska In Reply J. Clin. Oncol., January 20, 2008; 26(3): 510 - 511. [Full Text] [PDF]